ClinicalTrials.gg
TerminatedNCT04435782RESTOREUpdated Mar 30, 2025Results posted

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

A Phase 4 interventional study of JNJ-67896049 in Pulmonary Arterial Hypertension, sponsored by Actelion. Terminated at 35 sites in 15 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Why this study was terminated
The Sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing selexipag in Pulmonary Arterial Hypertension — 1 open to participants now, 3 under way, 1 of them phase 3. selexipag · Pulmonary Arterial Hypertension.

Enrollment
12th of 12
9 · median 67
Started
2021
the only one that year
Phase 4
3 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
9 of 12
Actelion

Among the 12 studies testing selexipag in Pulmonary Arterial Hypertension, this one is the 12th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 4, and was the 8th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies testing selexipag in Pulmonary Arterial Hypertension is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About selexipag

selexipag: first FDA approval 2015 (UPTRAVI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing selexipag in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Right ventricle
  • Reverse remodeling
  • Magnetic resonance Imaging
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • World health organization functional class (WHO FC) II or III. Enrollment will be stratified by WHO FC II or III. Proportion of participants with WHO FC II and WHO FC III are expected to be approximately 40 percent (%) and 60%, respectively
  • Pulmonary arterial hypertension (PAH) etiology belonging to one of the following groups according to 6th world symposium of pulmonary hypertension (WSPH) classification: a) Idiopathic PAH, b) Heritable PAH, c) Drugs or toxins induced d) PAH associated with connective tissue disease, e) PAH associated with congenital heart disease, with simple systemic-to-pulmonary shunt at least 1 year after surgical repair
  • Patients already receiving PAH-specific oral mono or dual therapy (that is, phosphodiesterase type 5 inhibitors [PDE-5i] or soluble guanylate cyclase stimulators [sGCs] and/or endothelin receptor antagonist [ERA]) or patients who are not candidates for these therapies
  • N-terminal-pro-hormone brain natriuretic peptide (NT-proBNP) greater than or equal to (>=) 300 nanograms per liter (ng/L) (greater than or equal to [>=] 300 picograms per milliliter [pg/mL]; >=35.5 picomoles per liter [pmol/L]) at screening
  • Women of must meet the following criteria: a) Have a negative serum pregnancy test during screening and a negative urine pregnancy test on Day 1, b) Agree to use acceptable methods of from Day 1 to at least 30 days after study intervention discontinuation, c) If only using hormonal contraception, have used it for at least 1 month (30 days) before Day 1, and d) Agree to perform monthly pregnancy tests to at least 30 days after study intervention discontinuation
  • 6-minute walking distance (6MWD) >=150 meter (m) during screening period

Exclusion criteria

Exclusion Criteria:

  • Prior use of Prostacyclin (IP)-receptor agonist, prostacyclin, or prostacyclin analog. Use of such treatments for vasoreactivity testing is not exclusionary; intermittent use of such treatments for digital ulcers or Raynaud's phenomenon is not exclusionary if stopped > 6 months (180 days) prior to Day 1
  • Treatment with strong inhibitors of CYP2C8 (example, gemfibrozil) within 4 weeks (28 days) prior to Day 1
  • Treatment with another drug planned or taken within 12 weeks (84 days) prior to Day 1
  • Severe coronary heart disease or unstable angina
  • Cerebrovascular events (example, , stroke) within 3 months (90 days) prior to Day 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    JNJ-67896049

    Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.

    Drug: JNJ-67896049

Interventions

  • Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.

    Also known as: Selexipag

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI)

    Change from baseline to Week 26 in RVSV assessed by pulmonary artery flow MRI was reported.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline to Week 26 in Right Ventricular End-Diastolic Volume (RVEDV) Assessed by MRI

    Change from baseline to Week 26 in RVEDV assessed by MRI was reported.

    Time frame: Baseline, Week 26

  2. Change From Baseline to Week 26 in Right Ventricular End-Systolic Volume (RVESV) Assessed by MRI

    Change from baseline to Week 26 in RVESV assessed by MRI was reported.

    Time frame: Baseline, Week 26

  3. Change From Baseline to Week 26 in Right Ventricular Ejection Fraction (RVEF) Assessed by MRI

    Change from baseline to Week 26 in RVEF assessed by MRI was reported. RVEF was the fraction of the end-diastolic volume (EDV) that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.

    Time frame: Baseline, Week 26

  4. Change From Baseline to Week 26 in Right Ventricular (RV) Mass Index Assessed by MRI

    Change from baseline to Week 26 in RV mass index assessed by MRI was reported.

    Time frame: Baseline, Week 26

  5. Change From Baseline to Week 26 in Right Ventricular Global Longitudinal Strain (RVGLS) Assessed by MRI

    Change in RVGLS was a measure of longitudinal percent change in length of endocardium at Week 26 from baseline length assessed by MRI.

    Time frame: Baseline, Week 26

  6. Number of Participants With Change From Baseline to Week 26 in World Health Organization (WHO) Functional Class

    WHO functional classification for PAH ranged from Class I (no limitation in physical activity, ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope), Class II (slight limitation of physical activity, ordinary physical activity cause undue dyspnea or fatigue, chest pain or near syncope), Class III (marked limitation of physical activity, less than ordinary activity cause undue dyspnea or fatigue, chest pain or near syncope) and Class IV (cannot perform a physical activity without any symptoms, dyspnea and/or fatigue may even be present at rest). Change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement =reduction in functional class; worsened =increase in functional class; and no change = no change in functional class.

    Time frame: Baseline, Week 26

  7. Change From Baseline to Week 26 in N-terminal-Pro-Hormone Brain Natriuretic Peptide (NT-proBNP)

    NT pro-BNP is a cardiac biomarker that is released in the blood in response to changes in the pressure inside of the heart. Levels go up when heart failure develops or gets worse, and levels go down when heart failure is stable or improves. This biomarker helps to measure the changes in the severity of heart failure over time in response to therapy.

    Time frame: Baseline, Week 26

  8. Change From Baseline to Week 26 in 6-Minute Walk Distance (6MWD)

    6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

    Time frame: Baseline, Week 26

  9. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. Any AE occurring at or after the initial administration of study intervention up to 3 days after last dose of study intervention was considered as treatment-emergent.

    Time frame: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)

  10. Number of Participants With Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug

    Number of participants with AEs leading to premature discontinuation of study drug were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: Day 1 up to last dose of study drug (up to Week 52)

  11. Number of Participants With Adverse Events of Special Interest (AESI)

    Number of participants with AESI were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AESI were anaemia, bleeding events, gastrointestinal disturbances denoting intestinal intussusception (manifested as ileus or obstruction), hyperthyroidism, hypotension, light-dependent non-melanoma skin malignancies, major adverse cardiovascular events (MACE), medication errors, ophthalmological effects associated to retinal vascular system, pregnancy, pulmonary venoocclusive disease associated with pulmonary oedema, renal function impairment / acute renal failure.

    Time frame: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)

  12. Number of Participants With Treatment-Emergent Marked Laboratory Abnormalities

    Number of participants with treatment-emergent marked laboratory abnormalities in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, creatinine, sodium, potassium, hemoglobin, hematocrit; EVF; PCV (male), hematocrit; EVF; PCV (female), platelets (assuming no platelet cluster), leukocytes; white blood cells, Neutrophils (Abs), Eosinophils (Abs), lymphocytes (Abs) were reported. Abnormalities that occurred after study treatment start and up to 3 days after study treatment discontinuation, that were not present at baseline, were treatment-emergent. Treatment-emergent marked laboratory abnormalities were determined at the investigator's discretion.

    Time frame: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)

  13. Change From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 8 Variables

    The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 8 variables: absence of clinical signs of right heart failure, absence of symptoms progression, absence of syncope, WHO FC I-II, 6MWD greater than (\>) 440 meter, NT-proBNP less than (\<) 300 ng/L, Right atrial (RA) area \<18 centimeter square (cm\^2) as determined by echocardiography (Echo), absence of pericardial effusion, as determined by Echo. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 8 variables for each participant can vary from 0 (worse participants) to 8 (healthier participants). Higher score indicated healthier participants.

    Time frame: Baseline, Week 26

  14. Change From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 3 Variables

    The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 3 variables: WHO FC I-II, 6MWD \>440 m, NT-proBNP \< 300 ng/L. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 3 variables for each participant can vary from 0 (worse participants) to 3 (healthier participants). Higher score indicated healthier participants.

    Time frame: Baseline, Week 26

07

Results

Posted Aug 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneSelexipag
Started9
Completed5
Not completed4
Withdrew: Study terminated by sponsor4

Outcome measures

PrimaryChange From Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI)

Change from baseline to Week 26 in RVSV assessed by pulmonary artery flow MRI was reported.

Time frame:
Baseline, Week 26
Reported as:
Number · Milliliter (mL)
Change From Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI)
Milliliter (mL)Selexipag
Participant 138.35
Participant 2-1.53
Participant 316.53
Participant 411
Participant 527.2
Participant 614.07
SecondaryChange From Baseline to Week 26 in Right Ventricular End-Diastolic Volume (RVEDV) Assessed by MRI

Change from baseline to Week 26 in RVEDV assessed by MRI was reported.

Time frame:
Baseline, Week 26
Reported as:
Number · Milliliter
Change From Baseline to Week 26 in Right Ventricular End-Diastolic Volume (RVEDV) Assessed by MRI
MilliliterSelexipag
Participant 140.57
Participant 2-8.89
Participant 323.58
Participant 46.79
Participant 53.71
Participant 67.82
SecondaryChange From Baseline to Week 26 in Right Ventricular End-Systolic Volume (RVESV) Assessed by MRI

Change from baseline to Week 26 in RVESV assessed by MRI was reported.

Time frame:
Baseline, Week 26
Reported as:
Number · Milliliter
Change From Baseline to Week 26 in Right Ventricular End-Systolic Volume (RVESV) Assessed by MRI
MilliliterSelexipag
Participant 12.23
Participant 2-7.36
Participant 37.05
Participant 4-4.22
Participant 5-23.5
Participant 6-6.25
SecondaryChange From Baseline to Week 26 in Right Ventricular Ejection Fraction (RVEF) Assessed by MRI

Change from baseline to Week 26 in RVEF assessed by MRI was reported. RVEF was the fraction of the end-diastolic volume (EDV) that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.

Time frame:
Baseline, Week 26
Reported as:
Number · Percentage of EDV
Change From Baseline to Week 26 in Right Ventricular Ejection Fraction (RVEF) Assessed by MRI
Percentage of EDVSelexipag
Participant 19.65
Participant 20.42
Participant 36.96
Participant 45.01
Participant 519.12
Participant 67.62
SecondaryChange From Baseline to Week 26 in Right Ventricular (RV) Mass Index Assessed by MRI

Change from baseline to Week 26 in RV mass index assessed by MRI was reported.

Time frame:
Baseline, Week 26
Reported as:
Number · Grams per meter square (g/m^2)
Change From Baseline to Week 26 in Right Ventricular (RV) Mass Index Assessed by MRI
Grams per meter square (g/m^2)Selexipag
Participant 1-11.03
Participant 22.72
Participant 3-12.69
Participant 40.09
Participant 5-16.56
Participant 6-2.41
SecondaryChange From Baseline to Week 26 in Right Ventricular Global Longitudinal Strain (RVGLS) Assessed by MRI

Change in RVGLS was a measure of longitudinal percent change in length of endocardium at Week 26 from baseline length assessed by MRI.

Time frame:
Baseline, Week 26
Reported as:
Number · Percent change in length of endocardium
Change From Baseline to Week 26 in Right Ventricular Global Longitudinal Strain (RVGLS) Assessed by MRI
Percent change in length of endocardiumSelexipag
Participant 1: RVGLS Endocardium-4.26
Participant 2: RVGLS Endocardium-5.31
Participant 3: RVGLS Endocardium-12.8
Participant 4: RVGLS Endocardium-5.61
Participant 5: RVGLS Endocardium-14.45
Participant 6: RVGLS Endocardium-1.74
SecondaryNumber of Participants With Change From Baseline to Week 26 in World Health Organization (WHO) Functional Class

WHO functional classification for PAH ranged from Class I (no limitation in physical activity, ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope), Class II (slight limitation of physical activity, ordinary physical activity cause undue dyspnea or fatigue, chest pain or near syncope), Class III (marked limitation of physical activity, less than ordinary activity cause undue dyspnea or fatigue, chest pain or near syncope) and Class IV (cannot perform a physical activity without any symptoms, dyspnea and/or fatigue may even be present at rest). Change from baseline in WHO functional class was classified into "Improved", "No change" and "Worsened". Improvement =reduction in functional class; worsened =increase in functional class; and no change = no change in functional class.

Time frame:
Baseline, Week 26
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline to Week 26 in World Health Organization (WHO) Functional Class
ParticipantsSelexipag
Baseline: Class I0
Baseline: Class II4
Baseline: Class III4
Baseline: Class IV0
Week 26: Improved3
Week 26: Unchanged5
Week 26: Worsened0
SecondaryChange From Baseline to Week 26 in N-terminal-Pro-Hormone Brain Natriuretic Peptide (NT-proBNP)

NT pro-BNP is a cardiac biomarker that is released in the blood in response to changes in the pressure inside of the heart. Levels go up when heart failure develops or gets worse, and levels go down when heart failure is stable or improves. This biomarker helps to measure the changes in the severity of heart failure over time in response to therapy.

Time frame:
Baseline, Week 26
Reported as:
Number · nanograms/liter (ng/L)
Change From Baseline to Week 26 in N-terminal-Pro-Hormone Brain Natriuretic Peptide (NT-proBNP)
nanograms/liter (ng/L)Selexipag
Participant 1-202.376
Participant 2142.9233
Participant 3-261.4904
Participant 478.6501
Participant 5-215.8226
Participant 6-762.5677
SecondaryChange From Baseline to Week 26 in 6-Minute Walk Distance (6MWD)

6MWD was the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

Time frame:
Baseline, Week 26
Reported as:
Number · Meter
Change From Baseline to Week 26 in 6-Minute Walk Distance (6MWD)
MeterSelexipag
Participant 1-72
Participant 20
Participant 3275
Participant 414
Participant 517
Participant 616
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. Any AE occurring at or after the initial administration of study intervention up to 3 days after last dose of study intervention was considered as treatment-emergent.

Time frame:
Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsSelexipag
AEs9
SAEs1
SecondaryNumber of Participants With Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug

Number of participants with AEs leading to premature discontinuation of study drug were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame:
Day 1 up to last dose of study drug (up to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug
ParticipantsSelexipag
Number of Participants With Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug0
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI)

Number of participants with AESI were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AESI were anaemia, bleeding events, gastrointestinal disturbances denoting intestinal intussusception (manifested as ileus or obstruction), hyperthyroidism, hypotension, light-dependent non-melanoma skin malignancies, major adverse cardiovascular events (MACE), medication errors, ophthalmological effects associated to retinal vascular system, pregnancy, pulmonary venoocclusive disease associated with pulmonary oedema, renal function impairment / acute renal failure.

Time frame:
Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI)
ParticipantsSelexipag
Number of Participants With Adverse Events of Special Interest (AESI)3
SecondaryNumber of Participants With Treatment-Emergent Marked Laboratory Abnormalities

Number of participants with treatment-emergent marked laboratory abnormalities in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, creatinine, sodium, potassium, hemoglobin, hematocrit; EVF; PCV (male), hematocrit; EVF; PCV (female), platelets (assuming no platelet cluster), leukocytes; white blood cells, Neutrophils (Abs), Eosinophils (Abs), lymphocytes (Abs) were reported. Abnormalities that occurred after study treatment start and up to 3 days after study treatment discontinuation, that were not present at baseline, were treatment-emergent. Treatment-emergent marked laboratory abnormalities were determined at the investigator's discretion.

Time frame:
Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Marked Laboratory Abnormalities
ParticipantsSelexipag
Number of Participants With Treatment-Emergent Marked Laboratory Abnormalities3
SecondaryChange From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 8 Variables

The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 8 variables: absence of clinical signs of right heart failure, absence of symptoms progression, absence of syncope, WHO FC I-II, 6MWD greater than (\>) 440 meter, NT-proBNP less than (\<) 300 ng/L, Right atrial (RA) area \<18 centimeter square (cm\^2) as determined by echocardiography (Echo), absence of pericardial effusion, as determined by Echo. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 8 variables for each participant can vary from 0 (worse participants) to 8 (healthier participants). Higher score indicated healthier participants.

Time frame:
Baseline, Week 26
Reported as:
Number · Score on a scale
Change From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 8 Variables
Score on a scaleSelexipag
Participant 11
Participant 21
Participant 33
Participant 41
Participant 51
Participant 61
SecondaryChange From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 3 Variables

The risk score is derived for each participant considering the following non-invasive low-risk criteria among the 3 variables: WHO FC I-II, 6MWD \>440 m, NT-proBNP \< 300 ng/L. Number of low-risk criteria at baseline and Week 26 constitutes risk score and were derived for each participant by adding '1' for each of above criteria met. Number of low-risk criteria among the 3 variables for each participant can vary from 0 (worse participants) to 3 (healthier participants). Higher score indicated healthier participants.

Time frame:
Baseline, Week 26
Reported as:
Number · Score on a scale
Change From Baseline to Week 26 in Number of Non-invasive Low-risk Criteria Among the 3 Variables
Score on a scaleSelexipag
Participant 11
Participant 20
Participant 32
Participant 41
Participant 51
Participant 61

Adverse events

Collected over All Cause Mortality: Day 1 up to 30 days after last dose of drug (up to Week 56), SAEs and non-SAEs: Day 1 up to 3 days after last dose of study drug (up to 52 weeks and 3 days that is 367 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selexipag0/9 (0%)1/9 (11.1%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventSelexipag
Cardiac FailureCardiac disorders1/9
Vaginal HaemorrhageReproductive system and breast disorders1/9
Most frequent other events
Showing 10 of 43
Most frequent other events
EventSelexipag
NauseaGastrointestinal disorders7/9
HeadacheNervous system disorders6/9
DiarrhoeaGastrointestinal disorders5/9
MyalgiaMusculoskeletal and connective tissue disorders5/9
Pain in JawMusculoskeletal and connective tissue disorders4/9
Covid-19Infections and infestations3/9
VomitingGastrointestinal disorders2/9
Chest PainGeneral disorders2/9
FatigueGeneral disorders2/9
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders2/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Selexipag
Mean42.2 ± 13.28
Age, Customized
Age, Customized(Participants)Selexipag
In utero0
Preterm newborn infants (gestational age < 37 wks)0
Newborns (0-27 days)0
Infants and toddlers (28 days-23 months)0
Children (2-11 years)0
Adolescents (12-17 years)0
Adults (18-64 years)9
From 65-84 years0
85 years and over0
Sex: Female, Male
Sex: Female, Male(Participants)Selexipag
Female6
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selexipag
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selexipag
American Indian or Alaska Native0
Asian7
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
08

Study locations

35 sites
  • University Of California San Diego
    La Jolla, California 92093, United States
  • AnMed Health
    Anderson, South Carolina 29621, United States
  • UT Southwestern
    Dallas, Texas 75231, United States
  • Hospital Italiano de Buenos Aires
    Caba, 1199ABB, Argentina
  • Sanatorio Ramon Cereijo
    Caba, C1048AAN, Argentina
  • Instituto Cardiovascular de Buenos Aires
    Ciudad Autonoma Buenos Aires, 1428, Argentina
  • Associacao Hospitalar Moinhos de Vento
    Porto Alegre, 90035-001, Brazil
  • Irmandade Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, 90035-074, Brazil
  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo
    Sao Paulo, 04024 002, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    Sao Paulo, 05403-000, Brazil
  • CHU Grenoble
    La Tronche, 38700, France
  • DRK Kliniken Westend
    Berlin, 14050, Germany
  • Universitatsklinikum Bonn
    Bonn, 53127, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz
    Mainz, 55131, Germany
  • Grantham Hospital
    Hong Kong, Hong Kong
  • Queen Mary Hospital University of Hong Kong
    Hong Kong, Hong Kong
  • Hadassah Medical Center
    Jerusalem, Israel
  • Rabin Medical Center Beilinson Campus
    Petah Tikva, 4941492, Israel
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Institut Jantung Negara
    Kuala Lumpur, 50400, Malaysia
  • VUMC Amsterdam
    Amsterdam, 1081 HV, Netherlands
  • Radboud Umcn
    Nijmegen, 6525 GA, Netherlands
  • National Medical Research Center of Cardiology of MoH of Russian Federation
    Moscow, 121552, Russian Federation
  • Federal State Budgetary Institution
    St Petersburg, 197341, Russian Federation
  • King Faisal Specialist Hospital & Research Center
    Riyadh, 12713, Saudi Arabia
  • National Heart Centre (NHC) Singapore
    Singapore, 169609, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • Cleveland Clinic Abu Dhabi
    Abu Dhabi, 112412, United Arab Emirates
  • Golden Jubilee National Hospital
    Glasgow, G81 4HX, United Kingdom
  • Royal Free Hospital
    Hampstead, NW3 2QG, United Kingdom
  • Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital
    Sheffield, S10 2RX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jul 2023, 24 months.

Results were first posted in Aug 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 17, 2020
StartActual
Jul 7, 2021
Primary completionActual
Jul 28, 2023
CompletionActual
Jul 28, 2023
Results first posted
Aug 20, 2024
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04435782
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jun 17, 2020
Start date
Jul 7, 2021
Primary completion
Jul 28, 2023
Completion
Jul 28, 2023
Results posted
Aug 20, 2024
Last update
Mar 30, 2025

Study contacts

Actelion Clinical Trial
study director · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selexipag

Start the discussion